Peptide education
Ipamorelin
Ipamorelin acetate · Ipamorelin free base
Ipamorelin is a five-amino-acid growth hormone secretagogue that works through the ghrelin receptor pathway, and its selling point is selectivity: in comparative endocrine work it raised GH without the ACTH and cortisol spillover seen with GHRP-2 and GHRP-6. That clean reputation is real pharmacology, and it is also most of what the evidence contains. The human record is one IV pharmacology study in healthy volunteers plus a postoperative-ileus program that never became an approved treatment. The fat-loss, muscle, sleep, recovery, and anti-aging programs built on it run on a subcutaneous route for which FDA found no route-specific safety or effectiveness data at all.
Ipamorelin earned its clean-secretagogue name in comparative pharmacology, then the human evidence all but stops: one IV study and a shelved bowel-surgery program. Everything the market sells it for happens on a route FDA says has no direct safety data.
Overview
Quick answer
The clearest human data are intravenous study schedules. The market usually talks about subcutaneous injections, nasal products, oral products, clinic programs, and combination vials. FDA's 2024 review specifically raised concerns about the lack of route-specific subcutaneous safety and effectiveness data. Those marketed products do not share the evidence base of the IV studies.
What is ipamorelin?
A synthetic pentapeptide ghrelin mimetic, usually sold as ipamorelin acetate, that prompts the pituitary to release growth hormone rather than supplying GH. Its distinguishing trait in comparative work was raising GH without the cortisol and ACTH spillover of older GHRPs.
What do people use or talk about it for?
Fat loss, lean mass, recovery, sleep, anti-aging, injury repair, collagen, cognition: FDA's own review documented this marketing across clinics, med-spas, and online sellers, often bundled with CJC-1295 or sermorelin. The breadth of the pitch is marketing data, not outcome data.
What study schedules and real-world patterns are reported?
The documented human schedules are intravenous and short: a dose-escalation pharmacology study in healthy volunteers, and a twice-daily IV program tested after bowel surgery. Clinics and forums instead run subcutaneous injections one to three times daily for 8 to 12 weeks, a pattern no published human study defines.
What is the main limitation?
The gap between the studied exposure and the sold exposure. A brief IV GH pulse in a controlled study does not establish what repeated subcutaneous vials do for body composition, sleep, or recovery, and FDA found no route-specific data to close that gap.
Reported practice
Commonly reported protocol
Clinic and community secretagogue protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
A healthy-volunteer PK/PD study reported dose-proportional pharmacokinetics and a short growth-hormone response after IV infusion. That supports GH-secretagogue activity; it does not show symptom or body-composition improvement.
FDA's review and the registry context keep postoperative ileus in the studied-use discussion, but the clinical outcome data did not lead to routine use.
FDA documented clinic, med-spa, and wellness marketing for weight loss, sleep, muscle, anti-aging, collagen, cognition, energy, inflammatory conditions, and recovery. Those are marketing claims, not measured human outcomes.
FDA raised concerns about physical and chemical characterization, impurities, aggregation, endotoxin information, route-specific safety, and the difference between free base and acetate forms.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Ipamorelin raises growth hormone. | This is the best-supported human statement. A healthy-volunteer PK/PD study using IV infusions reported a transient GH response and dose-proportional pharmacokinetics. | Ipamorelin is described as a ghrelin mimetic and GH secretagogue. The mechanism fits a pituitary GH-release signal. | Clinic and online discussions extrapolate from that hormone effect to broader wellness, body-composition, and recovery claims. | Supported for a short-term hormone response. That finding is not a promised clinical outcome. |
| Ipamorelin causes fat loss or body recomposition. | FDA's 2024 review did not identify a controlled human ipamorelin body-composition program for fat loss, lean-mass gain, cutting, or general weight-management outcomes. | GH biology can affect metabolism and body composition, which explains why the claim is popular. A body-composition claim still needs controlled human data showing weight, fat, lean mass, or performance changes. | Med-spa, wellness, concierge, vendor, and gray-market language commonly presents ipamorelin as a body-composition or "GH optimization" peptide, often alongside CJC-1295 or sermorelin. | Overstated. The marketed promise is much stronger than the available human outcome evidence. |
| Ipamorelin improves sleep, recovery, anti-aging, collagen, or cognition. | The cited ipamorelin human sources do not include controlled sleep, recovery, healthy-aging, collagen, or cognition outcomes. | A GH-axis signal makes these claims easy to market. The missing evidence is direct: trials showing people slept better, recovered faster, changed body composition, improved collagen markers, or improved cognition on ipamorelin itself. | FDA documented that these themes appear in clinic, med-spa, wellness, and online marketing. Forum and personal-use discussion usually treats them as subjective experiences rather than measured outcomes. | These are clinic-marketing and anecdotal-use themes. The cited ipamorelin studies do not measure those benefits. |
| Subcutaneous ipamorelin protocols are already settled. | The concrete study schedules are intravenous. FDA's review said it did not identify route-specific safety or effectiveness data for the proposed subcutaneous route. | Route matters for exposure, immune presentation, formulation, sterility, aggregation, and peptide-related impurity risk. | Subcutaneous vials and injection programs dominate clinic, vendor, and gray-market discussion, but popularity of that route does not supply subcutaneous PK, safety, or effectiveness data. | Subcutaneous use is common in the market, but the IV human studies do not define that use pattern. Route-specific human data remain a major gap. |
| A COA or purity percentage proves an ipamorelin vial matches study material. | The clinical studies do not resolve this. It is a manufacturing and lot-control question. | An injectable peptide can fail on identity, salt form, peptide-related impurities, aggregates, endotoxin, sterility, fill amount, storage, or reconstitution even if a listing advertises the molecule name. | Vendor pages often lean on purity or certificate language, while FDA's ipamorelin review raised characterization and impurity concerns that generic sales language does not settle. | A COA can be one limited data point. For an injectable product, the unresolved pieces are sterility, endotoxin, potency, storage, delivered dose, and traceability to the exact lot. |
Bottom line
Main takeaway
Ipamorelin is a GH-releasing peptide with a real acute hormone signal and a cleaner pharmacology profile than its older cousins. It is not an approved fat-loss, sleep, muscle, or anti-aging treatment, and the way it is actually used has no direct human safety record.
Separate three conversations that get merged: the IV pharmacology, the selectivity data, and the subcutaneous clinic-and-vendor market. Only the third one is what people buy, and it is the one with no controlled evidence.
The source hierarchy is short: the 1999 healthy-volunteer PK/PD study, the postoperative-ileus registry and program history, the comparative selectivity literature, and FDA's 2024 compounding review with the PCAC vote. Together they explain both the appeal and the rejection.
Identity
What it is
Ipamorelin is a synthetic pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, sold as the acetate salt or free base. It belongs to the ghrelin-mimetic branch of GH secretagogues: it presses the GH secretagogue receptor and lets the pituitary do the releasing.
Its claim to fame inside the class is selectivity. Comparative endocrine work found ipamorelin raised GH without the ACTH and cortisol increases that GHRP-2 and GHRP-6 produced, which is why community discussion treats it as the clean option and why clinics prefer it for wellness framing.
The human evidence behind all of this is thin and oddly routed. A 1999 study documented dose-proportional pharmacokinetics and a brief GH pulse after IV infusion, and a postoperative-ileus program tested twice-daily IV dosing after bowel surgery without turning into an approved or routine treatment. Nothing in the cited record is a subcutaneous body-composition, sleep, or recovery trial.
That route gap is the whole story of the modern market. The products people encounter are subcutaneous vials, nasal sprays, and oral forms, frequently stacked with CJC-1295 or sermorelin, and FDA's 2024 review found no route-specific safety or effectiveness data for the subcutaneous use before its advisory committee voted against allowing ipamorelin bulks in compounding.
How people talk about it online
Clinic, med-spa, and concierge marketing presents ipamorelin as GH optimization with a safety halo: the selective secretagogue for body composition, sleep, recovery, and anti-aging, usually stacked. FDA catalogued exactly this language and classified it as marketing, not evidence.
Forum reports are subjective by nature: sleep quality, recovery feel, appetite, injection timing. They explain the appeal, but they come without product verification, objective endpoints, or adverse-event follow-up, and the stack formats make single-drug attribution impossible.
Vendor listings sell injectable, nasal, and oral forms with purity and COA language, while FDA's review flagged missing characterization, impurity, aggregation, and endotoxin information for ipamorelin materials. The acetate-versus-free-base distinction on those listings is a real product question, not a synonym.
Use context
Routes, doses, and cycle patterns
The study schedules are IV and short-term. The public market usually talks about repeated subcutaneous injection programs, nasal or oral products, and secretagogue stacks. IV studies explain the hormone signal; clinic and gray-market routines show how people market and discuss it, not whether those routines produce the claimed effects.
Human studies and product labels
Healthy-volunteer PK/PD study
- Purpose
- Acute growth-hormone response and pharmacokinetics
- Context
- Human dose-escalation pharmacology study
- Route
- Intravenous infusion
- Amount
- 4.21, 14.02, 42.13, 84.27, or 140.45 nmol/kg
- Frequency
- Single 15-minute infusion at each studied dose level
- Duration
- Short-term sampling after dosing
This pattern supports an acute GH-response and PK statement. It does not test fat loss, muscle gain, sleep, recovery, anti-aging, or chronic subcutaneous use.
Postoperative-ileus clinical program
- Purpose
- Recovery of gastrointestinal function after bowel surgery
- Context
- ClinicalTrials.gov and FDA-reviewed investigational context
- Route
- Intravenous
- Amount
- 0.03 mg/kg
- Frequency
- Twice daily
- Duration
- Up to 7 days, beginning postoperative day 1, or until discharge
This is the primary clinical-outcome context connected to ipamorelin in the current materials. It did not turn ipamorelin into approved or routine postoperative care.
Real-world discussion
Clinic and community secretagogue protocols
- Purpose
- Recovery, sleep, and body-composition discussion
- Context
- Clinics, med-spas, forums, and vendor listings
- Route
- Subcutaneous injection
- Amount
- Community protocols usually describe 100 to 300 mcg per injection, one to three times daily, usually fasted: on waking, after training, or before bed.
- Frequency
- One to three times daily in most community descriptions
- Duration
- Commonly described in 8 to 12 week cycles
Ipamorelin is favored in community discussion for its relative selectivity: comparative endocrine work found it did not raise ACTH or cortisol where GHRP-2 and GHRP-6 did, but controlled human outcome data for the marketed uses are absent. Reported as context, not a recommendation.
Stacking discussion with GHRH analogs
- Purpose
- Amplifying GH pulses
- Context
- Clinics and forums
- Route
- Subcutaneous injection
- Amount
- Commonly described as 100 to 300 mcg of ipamorelin paired with an equal amount of CJC-1295 no DAC or sermorelin per injection
- Frequency
- One to three times daily, often a single pre-bed combination
- Duration
- Commonly 8 to 12 weeks
The GHRH-plus-secretagogue pairing mirrors the synergy seen in endocrine studies, but the combination products sold are unverified and the outcomes marketed are untested.
What varies
- Source: IV pharmacology shows short-term hormone behavior; registry entries show what was studied; clinic, vendor, and forum sources show marketing and personal-use patterns.
- Route: the available human studies support IV study description better than repeated subcutaneous, nasal, or oral market use.
- Combination status: ipamorelin alone is different from CJC-1295/ipamorelin, Modified GRF/ipamorelin, or sermorelin/ipamorelin stacks.
- Product form: free base, acetate, compounded product, and research-use vial raise different identity and quality questions.
Human data
Human evidence
The direct human evidence fits in two short paragraphs: a 1999 IV pharmacology study showing a transient GH pulse and dose-proportional pharmacokinetics in healthy volunteers, and a postoperative-ileus program that supplied a clinical setting but no approved use. FDA's 2024 review then did the market's homework: it found no FDA-approved ipamorelin product, no controlled human data behind the wellness and body-composition claims, and no route-specific safety or effectiveness data for subcutaneous use. The advisory committee voted against placing ipamorelin substances on the 503A bulks list. Selectivity makes ipamorelin the best-behaved secretagogue on paper; it does not substitute for the outcome trials that never happened.
Evidence maturity
Ipamorelin's clean selectivity profile never translated into outcome trials or compounding access.
1999 pharmacokinetic study in healthy volunteers.
No ACTH or cortisol spillover at GH-effective doses in comparative work.
None for recovery, body composition, or anti-aging.
Failed the 2024 PCAC vote for 503A bulk use; gray market persists.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Healthy-volunteer PK/PD study | Healthy male volunteers | Dose-escalation pharmacokinetic/pharmacodynamic study | Investigational IV study material | IV ipamorelin produced dose-proportional pharmacokinetics and a short GH response, with the hormone peak occurring soon after dosing. | This was a biomarker and disposition study. Chronic safety, patient-centered benefit, body-composition change, sleep, recovery, and subcutaneous use are outside that design. | moderate |
| Postoperative-ileus clinical context | Adults after bowel resection or postoperative GI recovery context | Registry and FDA-reviewed investigational clinical program | Investigational IV clinical material | Postoperative ileus was studied as a clinical context, but the current evidence did not turn ipamorelin into an approved or routine treatment. | A bowel-surgery IV study belongs to that surgical context, not wellness, body-composition, anti-aging, sleep, recovery, or gray-market injection use. | weak |
| FDA 2024 compounding review | Proposed compounded-use contexts for growth hormone deficiency and postoperative ileus | FDA review and Pharmacy Compounding Advisory Committee discussion | Ipamorelin free base and ipamorelin acetate bulk-substance review | FDA found no FDA-approved drug product containing ipamorelin, raised safety and quality concerns, and PCAC voted against placing the ipamorelin substances on the 503A Bulks List. | A compounding-policy review is not a full drug-development report, but it is directly relevant to the way clinics and peptide vendors market the compound. | moderate |
Cautions
Safety and unknowns
- Long-term endocrine safety is still unanswered for the broad wellness uses attached to ipamorelin. The same concerns that follow GH-axis stimulation, including glucose handling and IGF-1-related monitoring questions, matter even when ipamorelin is marketed as "selective."
- FDA's review did not identify safety data for the proposed subcutaneous route, even though subcutaneous injection is central to the clinic and gray-market conversation.
- The postoperative-ileus studies included adverse-event concerns in FDA's discussion, including events such as hypokalemia, insomnia, hyperglycemia, nausea, vomiting, and abdominal distention. Those events matter because they appeared in FDA's review, even though they do not prove causality in every setting.
- There is no strong human evidence for repeated ipamorelin use in healthy people seeking sleep, anti-aging, muscle, fat-loss, or recovery effects.
Product quality
A vial label is only a starting point
FDA highlighted missing or inadequate information on physical and chemical characterization, impurities, aggregates, endotoxins, and certificates of analysis for reviewed ipamorelin materials.
Ipamorelin free base and ipamorelin acetate are not just marketing synonyms. The form, solubility, formulation, storage, and injectable quality questions affect which evidence applies.
For market vials, a purity claim still does not answer sterility, endotoxin, peptide-related impurity, aggregation, identity, fill amount, and chain-of-custody questions.
Identity
The product has to be the claimed peptide and form, not just a label using the ipamorelin name.
Route-specific formulation
A marketed subcutaneous vial raises different formulation and sterility questions from the IV product used in studies.
Peptide-related impurities
Peptide impurities can affect safety, immune response, and potency.
Aggregation and endotoxin
These are especially important for injectable products and were part of FDA's product-quality concern.
Certificate of analysis
A COA only helps if it covers the tests that matter for the exact lot and intended product form.
Mechanism
How it is proposed to work
Ipamorelin mimics part of the ghrelin signaling pathway. It activates the growth hormone secretagogue receptor pathway and prompts the pituitary to release growth hormone for a short period after exposure.
The healthy-volunteer PK/PD study connects that mechanism to people by showing an acute GH pulse after IV infusion.
Preclinical pharmacology is often described as more selective than older GHRPs because it appeared to stimulate GH with less ACTH or cortisol stimulation in animal work. That supports a mechanism and selectivity discussion, but it does not answer broad human safety questions.
The postoperative-ileus rationale came from ghrelin-pathway effects on GI motility, but the human clinical outcome evidence did not become a clear positive use.
Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin-receptor (GHS-R1a) agonist. Its distinguishing pharmacology is selectivity: in comparative endocrine work it raised GH without the ACTH and cortisol spillover seen with GHRP-2 and GHRP-6 at comparable doses.
FAQ
Common questions
Is ipamorelin an approved growth-hormone-deficiency or anti-aging peptide?
No. FDA's 2024 briefing says ipamorelin free base and acetate are not components of an FDA-approved drug, and the PCAC discussion weighed against adding them to the 503A Bulks List for the reviewed GHD and postoperative-ileus contexts.
Does the postoperative-ileus study context make ipamorelin established care?
No. Postoperative ileus appears here as registry context plus FDA review context. That keeps the subject visible as investigation, not as approved or routine care.
Are practical directions included?
No practical preparation, access, or combined-use details are supported by the cited sources. The evidence is mainly about strength of support and regulatory status.
Details
Technical details
Sources
References
- 1.
FDA. FDA Briefing Document: Ipamorelin-related bulk drug substances 2024.
Accessed 2026-06-09.
FDA PCAC briefing covering ipamorelin free base and acetate, the evaluated GHD and postoperative-ileus contexts, no FDA-approved drug product, and FDA's recommendation against 503A Bulks List inclusion.
- 2.
FDA. October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting 2024.
Accessed 2026-06-09.
FDA meeting summary reporting PCAC votes against placing ipamorelin free base or ipamorelin acetate on the 503A Bulks List because the available information did not support safety and efficacy in the reviewed contexts.
- 3.
ClinicalTrials.gov. ClinicalTrials.gov record NCT01280344
Accessed 2026-06-09.
Official registry page for the ipamorelin postoperative-ileus / gastrointestinal-function recovery study context referenced in the FDA briefing; used for registry context, not outcome conclusions.
- 4.
PubMed. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers 1999.
doi:10.1023/A:1018955126402 PMID:10496658 Accessed 2026-06-09.
Healthy-volunteer dose-escalation PK/PD study showing dose-proportional exposure and a transient growth-hormone response; useful for narrow human pharmacology context, not patient-outcome or wellness claims.